25 results about "Bladder cancer" patented technology

A method for treating bladder cancer is provided at this institution.

The application provides a urine exosome-based bladder cancer gene detection system and application, and relates to the technical field of biological detection. Through the cooperative application of the internal reference gene and the diagnosis model, the application provides a reliable endogenous quality control standard for the bladder tissue-derived exosome in the urine exosome sample; meanwhile, the application realizes non-invasive, accurate, rapid screening, diagnosis, prognosis and recurrence monitoring of bladder cancer, lays a key technical foundation and detection tool for the urine exosome-based molecular diagnosis of bladder cancer, and has important clinical transformation value and application prospect.

Provided herein are methods of treatment, erdafitinib for use and use of erdafitinib for the treatment of bladder cancer harboring one or more FGFR alterations comprising locally delivering erdafitinib into the bladder of a patient.

Provided herein are therapeutic methods for use in treating bladder cancer, the therapeutic methods comprising administration of erdafitinib and drug delivery systems comprising erdafitinib.

The application discloses a series of derivatives based on natural product gelsemium methyl, pharmaceutically acceptable salts and preparation methods thereof. Bioactivity tests show that the compounds have the effect of inhibiting the proliferation of various tumor cells. The compounds can be used for the treatment of various cancers (including but not limited to gastric cancer, liver cancer, lung cancer, esophageal cancer, cervical cancer, breast cancer, colon cancer, rectal cancer, nasopharyngeal cancer, ovarian cancer, kidney cancer, bladder cancer, thyroid cancer and skin cancer) as active pharmaceutical ingredients.

A method of treating bladder cancer with an agonistic IL-15 complex, alone or in combination with BCG, is described.

The application discloses a bladder cancer diagnosis and treatment integrated system and a control method thereof, which comprises a swept-frequency OCT light source, a treatment laser, a wavelength division multiplexer, a double-clad optical fiber, a flexible scanning probe, an endoscope imaging unit and an intelligent image processing and control terminal; imaging light and treatment laser are transmitted in a common light path by using the double-clad optical fiber, and scanning and light beam control are completed by means of a double-axis MEMS micro-mirror. The control method obtains tomographic structure information and depth information by reconstructing OCT data, and controls treatment laser power, galvanometer deflection and laser pause, recovery or stop by combining distance calculation, displacement compensation and blood perfusion monitoring, and is suitable for imaging navigation and closed-loop treatment in bladder cancer surgery.

This invention relates to gene constructs, expression cassettes comprising said gene constructs, and oncolytic viruses, and their use in methods for treating, preventing, or alleviating cancer. The gene constructs, expression cassettes, and oncolytic viruses are particularly useful (but not limited to) for treating bladder cancer, such as non-muscle-invasive bladder cancer.

The application discloses application of coccinellin in antitumor drugs and the drugs, wherein the coccinellin has a molecular formula of C 14 H 10 N2O5, and the tumor includes at least one of colorectal cancer, pancreatic cancer, lung cancer, liver cancer, gastric cancer, thyroid cancer, kidney cancer, bladder cancer, ovarian cancer, cervical cancer, breast cancer, myeloma, hemangioma and central nervous system tumor. The antitumor mechanism of the coccinellin is to inhibit KRAS G12D mutant subtype. The coccinellin can effectively inhibit proliferation of various tumor cells, and is expected to be applied to tumor treatment as an antitumor small molecule targeted drug.

This invention provides a dual-target nucleic acid aptamer, conjugate, preparation method, and application. Using Nectin4 and c-Met as dual targets, this invention designs and constructs a dual-target nucleic acid aptamer-MMAE conjugate. Stable conjugation between the nucleic acid aptamer and MMAE is achieved through a maleimide-thiol specific reaction. Through systematic structural characterization, in vitro functional verification, and in vivo imaging and therapeutic studies, the invention verifies the conjugate's targeting ability for bladder cancer, in vitro antitumor activity, and in vivo tumor enrichment and growth inhibition effects. This addresses the problem of insufficient MMAE targeting, providing a new experimental model and theoretical basis for nucleic acid aptamer-mediated targeted delivery of small molecule cytotoxic drugs, and exploring new strategies for dual-target precision treatment of bladder cancer.

A novel micropeptide, MP36, and its applications are provided. This MP36 micropeptide can be used to prepare reagents or drugs for the detection, prevention, or treatment of tumors, including one or more of lung cancer, breast cancer, colon cancer, glioma, bladder cancer, gastric cancer, head and neck cancer, and sarcoma. In tumors, the MP36 micropeptide can inhibit tumor cell growth and / or metastasis by specifically inhibiting MP36 expression via small interfering RNA; or by overexpressing MP36 to inhibit tumor cell growth and / or metastasis; or by conjugating a membrane-penetrating peptide to inhibit tumor growth and / or metastasis. It has significant value for new drug development and tumor detection.

The application relates to immunoconjugates for use in a method of treating bladder cancer in a human patient, wherein the method comprises administering the immunoconjugate to the patient, wherein the immunoconjugate comprises: (i) an antibody that binds to PD-1; and (ii) a mutant IL-2 polypeptide comprising the amino acid substitutions F42A, Y45A and L72G. The immunoconjugates are capable of binding in cis to PD-1 and stimulating IL-2 signalling on the same cell, providing selective IL-2 receptor signalling on PD-1 positive T cells relative to the PD-1 negative T cells. The application also relates to the use of the immunoconjugates in combination with immunotherapeutic agent, which is bacterial strain or an oncolytic virus, such as the BCG vaccine.

A chimeric antigen receptor targeting glycoprotein A repeat dominant protein (GARP) and its use in the treatment of cancers, including but not limited to breast cancer, bladder cancer, glioblastoma, leukemia, or other malignancies characterized by GARP+Treg, are disclosed.

The present disclosure relates to methods of treating triple negative breast cancer or non-muscle invasive bladder cancer in a subject comprising administering to the subject a composition comprising non-viable cells of Streptococcus pyogenes and an immune checkpoint inhibitor.

The application provides a urine exosome-based bladder cancer gene detection system and application, and relates to the technical field of biological detection. Through the cooperative application of the internal reference gene and the diagnosis model, the application provides a reliable endogenous quality control standard for the bladder tissue-derived exosome in the urine exosome sample; meanwhile, the application realizes non-invasive, accurate, rapid screening, diagnosis, prognosis and recurrence monitoring of bladder cancer, lays a key technical foundation and detection tool for the urine exosome-based molecular diagnosis of bladder cancer, and has important clinical transformation value and application prospect.

An improved diagnostic assay and methods relating to the same that are directed to mutation focused disease diagnosis and surveillance biomarker panels wherein potential genomic regions are selected based on their ability to encompass the genomic diversity of a patient population, maximize the number of unique markers monitored within each patient are maximized while balancing these factors with empirical sequencing performance, geographic clustering of events with a region across diverse patients, and size and cost associated with measuring the respective genomic region. The methods also include quality control steps to reduce noise.

It was found that SDF4 in a body fluid sample can be a marker for detecting a cancer patient with good sensitivity and specificity. By using a reagent for specifically detecting the SDF4, it is possible to detect gastric cancer, breast cancer, colorectal cancer, pancreatic cancer, esophageal cancer, hepatic cancer, liposarcoma, bladder cancer, brain tumor, head and neck cancer, gallbladder cancer, ovarian cancer, tongue cancer, or uterine cancer. The measurement of the SDF4 in the body fluid sample is a test method capable of detecting various types of cancer with a single test, and can be used for mass screening for cancer. Further, it is capable of detecting even cancer of an early stage with good sensitivity and specificity, and thus is capable of detecting cancer at an early stage to start a treatment.

The present disclosure relates to methods, compositions, and kits for concentrating and purifying one or more target analyte (s) from a bulk fluid sample. In some embodiments, the methods involve at least two first aqueous two-phase system (ATPS) compositions. Some embodiments provide a kit comprising at least two ATPS compositions, and a binding buffer. Other embodiments provide methods of treating bladder cancer in a patient in need thereof.

Short expansion mutations in PABPN1 cause adult-onset, autosomal dominant oculopharyngeal muscular dystrophy (OPMD). The molecular hallmark of OPMD is the presence of insoluble nuclear aggregates of the expanded (exp)PABPN1. The aggregation of PABPN1 results in reduced levels of functional PABPN1. In OPMD, PABPN1 levels are under a critical threshold which leads to muscle weakness. Interestingly, reduced levels of PABPN1 are also found in ageing muscles, where these reduced levels lead to muscle atrophy and has also been found to be associated with other adult-onset pathologies affecting tissues other than skeletal muscles, such as cancers, including bladder cancer, and heart diseases.

Disclosed herein are antibody-drug conjugates (ADCs) in which a drug moiety is conjugated to an antibody or antigen-binding fragment that binds to TROP2, and methods of use thereof. Methods of use include the treatment and diagnosis of cancer. The ADCs of this disclosure may bind to the surface of specific cancer cells. Exemplary targets of the ADCs disclosed herein may include cancers such as lung cancer, breast cancer, head and neck cancer, esophageal cancer, gastric cancer, bladder cancer, pancreatic cancer, colorectal cancer, cervical cancer, endometrial cancer, ovarian cancer, laryngeal cancer, prostate cancer, thyroid cancer, and oral cancer.

This invention discloses a lateral flow chromatography test strip based on liposome-gold hybrid material, comprising a base plate and a sample pad, a conjugation pad, a reaction membrane, and an absorbent pad sequentially connected to the base plate along the chromatography direction. A detection line and a control line are sequentially arranged on the reaction membrane along the chromatography direction. The liposome-gold hybrid material modified with a detection probe contained in the conjugation pad, the streptavidin-modified capture probe contained in the detection line, and the target miRNA can specifically bind to the detection line to form a sandwich structure and develop color. The streptavidin-modified control probe contained in the control line can capture the liposome-gold hybrid material modified with the detection probe and develop color. This lateral flow chromatography test strip detects target miRNA based on the color development and intensity of the detection line, exhibiting high sensitivity and accuracy, low detection limit, good repeatability, short detection time, and simple operation. It requires only one sample addition step to detect one or more bladder cancer biomarkers, eliminating the need for complex instruments and equipment, and is cost-effective, showing promising application prospects in in vitro rapid detection.